Adecto Pharmaceuticals is a pre-clinical stage cancer therapeutics company based in Brookline, MA. They are dedicated to developing the first targeted therapy against aggressive ADAM8-positive cancers and a companion diagnostic to identify patients who can benefit from it.
With over 30 years of research, Adecto Pharmaceuticals aims to stop primary cancer growth and metastases by targeting the ADAM8 protein expressed on the cancer cell surface. Their initial focus is on breast cancer, but they plan to expand to other oncology indications in the future, potentially benefiting over 2 million patients globally with ADAM8-positive cancers.
Generated from the website